PSTV - Plus Therapeutics Inc

Recent News

This BorgWarner Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Plus Therapeutics ( NASDAQ:PSTV ) , BorgWarner ( NYSE:BWA )

Benzinga • 1 week, 5 days ago • score: 0.46

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics, Inc.

Neutral

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 5 days ago • score: 0.05

HOUSTON, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Plus Therapeutics, Inc. ( Nasdaq: PSTV ) ( "Plus" or the "Company" ) , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ( CNS ) cancers, announces that it ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing, and commercialization of treatments for patients with cancer and other diseases. The company is headquartered in Austin, Texas.

52W High

$2.31

52W Low

$0.16

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.66

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.30

EV/Revenue (<3 favorable)

18.19

P/S (TTM) (<3 favorable)

9.17

P/B (<3 favorable)

16.08

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

1.77%

Institutions (25–75% balanced)

1.27%

Shares Outstanding

99,264,000

Float

99,057,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

5,317,000

Gross Profit (TTM)

-2,729,000

EPS (TTM)

-1.39

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1.11%

ROE (TTM) (>15% strong)

-5.22%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.09

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—